Blood test approved by FDA for colorectal cancer detection in individuals aged 45 and older, offering an additional screening option.
Detection limitations: The Shield test may not detect early-stage colorectal cancer and misses 87% of precancerous growths, not replacing a colonoscopy.
State of play: Shield test by Guardant to launch soon with FDA approval, becoming the first blood test for colorectal cancer for average-risk individuals eligible for Medicare coverage.